Navigation Links
Signum Dermalogix Investigational New Drug (IND) Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea
Date:7/9/2013

PRINCETON, N.J., July 8, 2013 /PRNewswire/ -- Signum Dermalogix, Inc. ("Dermalogix") a private biopharmaceutical company focused on developing new and innovative dermatological products and services announced that its Investigational New Drug (IND) Application to evaluate SIG990 in rosacea has been cleared by the U.S. Food and Drug Administration (FDA).

SIG990 is a safe topical treatment that addresses both erythema and inflammatory lesions and thus would be a significant and potentially better therapeutic option for rosacea patients then what is currently on the market. SIG990 is an isoprenylcysteine (IPC) analog that modulates toll-like receptor (TLR) and G-protein signaling demonstrating promising results in several in vitro cell based assays and efficacy in in vivo topical inflammatory animal models.

Instrumental in the pre-clinical development of SIG990 was funding from the National Institute of Allergy and Infectious Diseases (NIAID) via an SBIR grant. Dr. Eduardo Perez, VP of R&D and Business Development stated, "We thank NIAID for their support of this program. We would not have been able to perform the critical safety, pharmacology and manufacturing required without this grant support."

As a new chemical entity, SIG990 recently had composition of matter IP awarded (US Patent Application No. 12/566,839). Maxwell Stock, CEO of Dermalogix, commented, "We continue to make significant progress and are well-positioned to advance the development of our IPC compounds in dermatology. I look forward to moving SIG990 into the clinic to assess its efficacy in human subjects."

About Signum Dermalogix
Signum Dermalogix, is a dermatological focused company, developing novel cosmetic ingredients and drug compounds. Dermalogix also provides dermatology testing, custom assay development and analytical services. For more information pl
'/>"/>

SOURCE Signum Dermalogix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
2. Data from Study of Elderly Depressed Patients are Reported for Investigational Compound Lu AA21004 on Symptoms of Major Depressive Disorder (MDD)
3. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Abbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinsons Disease
8. Results For Phase 2b Trial Of Unique Investigational Cell-Based Therapy In Venous Leg Ulcers Published In The Lancet
9. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
10. Clinical Study With Investigational Cream Aims To Help Women Who Experience Painful Sex
11. Omeros Files Investigational New Drug Application for Lead Compound in PDE10 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... BAUDETTE, Minn. , July 28, 2014  ANI ... that the Company plans to release its second quarter ... 2014, before the opening of the U.S. financial markets. ... Investor Relations section of the Company,s website, www.anipharmaceuticals.com ... and Chief Executive Officer, and Charlotte C. Arnold ...
(Date:7/28/2014)... 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... Financial Results and Highlights Conference CallWhen:Monday, August 4 at ... How:Live on the Internet. Simply log onto our website ... the live event, a replay of the webcast will ... . ABOUT ISIS PHARMACEUTICALS, INC. Isis is ...
(Date:7/28/2014)... , Germany and ... , Collaboration aims to create and ... to guide the use of IRESSA  for non-small cell ... build on QIAGEN,s FDA-approved  therascreen   EGFR test and is ... of automated instruments  Project enabled by AstraZeneca ...
Breaking Medicine Technology:ANI Pharmaceuticals Schedules Conference Call for Second Quarter 2014 Financial Results 2Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6
(Date:7/28/2014)... researchers report that an alternative to the traditional handshake ... experiments, the scientists found that clasping hands transferred about ... other than what is known as a fist bump. ... a cultural substitute for the firm gripping of hands. ... of the American Journal of Infection Control . ...
(Date:7/28/2014)... Washington, DC (PRWEB) July 28, 2014 ... recipe app for iOS, App is available on iTunes for ... first of its kind, Audio Chef allows you to listen ... gourmet cuisine the easy way: simply get out the ingredients ... no need to measure or prepare ingredients ahead of time, ...
(Date:7/28/2014)... meal you,ve ordered at a restaurantor when something ... your brain. , These waves are called ... cellsboth excitatory and inhibitoryplaying together in an orchestrated ... waves have been associated with higher-level brain function, ... to schizophrenia, Alzheimer,s disease, autism, epilepsy and other ...
(Date:7/28/2014)... 28, 2014 UT Southwestern Medical Center cancer ... irreversibly interferes with the activity of a mutated ... , The molecule, SML-8-73-1 (SML), interferes with the ... homolog. The gene produces proteins called K-Ras that ... result in normal cells dividing uncontrollably and turning ...
(Date:7/28/2014)... 2014 The report, “Blowing Agents ... - Trends and Forecasts to 2019” defines and ... and forecasting of the global consumption volume and ... tables with 39 figures spread through 226 Pages ... http://www.marketsandmarkets.com/Market-Reports/blowing-agents-market-71329121.html , Blowing agents are highly utilized ...
Breaking Medicine News(10 mins):Health News:'Fist Bump' May Beat Handshake for Cleanliness 2Health News:'Fist Bump' May Beat Handshake for Cleanliness 3Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 2Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 3Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 4Health News:Memory relies on astrocytes, the brain's lesser known cells 2Health News:Memory relies on astrocytes, the brain's lesser known cells 3Health News:UTSW cancer researchers identify irreversible inhibitor for KRAS gene mutation 2Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 2Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 3Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 4
... debate is still on. Is Hormone Replacement Therapy (HRT), good ... caution. The treatment, which targets menopausal women by giving them ... two -edged sword. Its risks such as breast cancer, and ... traumatic menopausal symptoms. This was mainly due to a 2002 ...
... have criticized Prime Minister John Howard for calling for a ... there was no evidence to suggest migrants were responsible for ... Minister Howard had made the suggestion in an interview to ... sharp rise in HIV cases. ,Don Baxter, ...
... forces to perfect a powerful new weapon in the war ... spores. //Their results are published in the prestigious journal Science, ... to use lasers to detect anthrax in real time as ... now,” says Marlan Scully, Distinguished Professor of Physics at Texas ...
... sexually transmitted disease, has become so drug resistant now ... options to treat this serious disease. ,Doctors prescribe ... ofloxacin, and levofloxacin) as a treatment for the disease. ... and Prevention (CDC) says that the sexual disorder-that affects ...
... are now looking at lactate with a much more ... the brain in the immediate //hours after a traumatic ... they are right, it could change how emergency room ... injuries in the first critical hours after injury. ...
... Viagra, Cialis, and Levitra are the answer to their ... a new report from Harvard Medical School, these pills ... pressures that frequently accompany erectile dysfunction (ED). ... man is feeling sexual desire for his partner. If ...
Cached Medicine News:Health News:Hormone Replacement Therapy – To Choose Or No 2Health News:HIV Experts Criticize Australian PM's Suggestion for Ban on Entry of HIV-infected 2Health News:Physicists Unite To Develop Anthrax Detection Method 2Health News:Physicists Unite To Develop Anthrax Detection Method 3Health News:Physicists Unite To Develop Anthrax Detection Method 4Health News:Scientists Concerned About Gonorrhea’s Drug Resistanc 2Health News:Study Challenges Conventional Treatment of Traumatic Brain Injury 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: